173 related articles for article (PubMed ID: 24712728)
1. Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia.
Boons CC; Swart EL; Timmers L; van de Ven PM; Janssen JJ; Hugtenburg JG
BMC Cancer; 2014 Apr; 14():247. PubMed ID: 24712728
[TBL] [Abstract][Full Text] [Related]
2. Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib.
Boons CCLM; Timmers L; Janssen JJWM; Westerweel PE; Blijlevens NMA; Smit WM; Bartelink IH; Wilschut JA; Swart EL; Hendrikse NH; Hugtenburg JG
Eur J Clin Pharmacol; 2020 Sep; 76(9):1213-1226. PubMed ID: 32488333
[TBL] [Abstract][Full Text] [Related]
3. Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice.
Huguet F; Cayuela JM; Cambier N; Carpentier N; Tindel M; Violet I; Zunic P; Lascaux A; Etienne G;
Br J Haematol; 2019 Dec; 187(5):615-626. PubMed ID: 31394591
[TBL] [Abstract][Full Text] [Related]
4. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
Giles FJ; Yin OQ; Sallas WM; le Coutre PD; Woodman RC; Ottmann OG; Baccarani M; Kantarjian HM
Eur J Clin Pharmacol; 2013 Apr; 69(4):813-23. PubMed ID: 23052406
[TBL] [Abstract][Full Text] [Related]
5. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
[TBL] [Abstract][Full Text] [Related]
6. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
[TBL] [Abstract][Full Text] [Related]
7. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
8. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
[TBL] [Abstract][Full Text] [Related]
9. Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study.
Sacha T; Góra-Tybor J; Wąsak-Szulkowska E; Kyrcz-Krzemień S; Mędraś E; Becht R; Bober G; Kotowska A; Wącław J; Hellmann A
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):283-295. PubMed ID: 28185798
[TBL] [Abstract][Full Text] [Related]
10. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.
Shin J; Koh Y; Yoon SH; Cho JY; Kim DY; Lee KH; Kim HJ; Ahn JS; Kim YK; Park J; Sohn SK; Moon JH; Lee YJ; Yoon S; Lee JO; Cheong JW; Kim KH; Kim SH; Kim HG; Kim H; Nam SH; Do YR; Park SG; Park SK; Bae SH; Song HH; Shin DY; Oh D; Kim MK; Jung CW; Park S; Kim I
Cancer Med; 2018 May; 7(5):1814-1823. PubMed ID: 29577674
[TBL] [Abstract][Full Text] [Related]
11. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
[TBL] [Abstract][Full Text] [Related]
12. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
[TBL] [Abstract][Full Text] [Related]
13. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of and patients' perspective on nilotinib dried blood spot self-sampling.
Boons CCLM; Timmers L; Janssen JJWM; Swart EL; Hugtenburg JG; Hendrikse NH
Eur J Clin Pharmacol; 2019 Jun; 75(6):825-829. PubMed ID: 30729257
[TBL] [Abstract][Full Text] [Related]
16. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
[TBL] [Abstract][Full Text] [Related]
17. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.
Nicolini FE; Masszi T; Shen Z; Gallagher NJ; Jootar S; Powell BL; Dorlhiac-Llacer PE; Zheng M; Szczudlo T; Turkina A
Leuk Lymphoma; 2012 May; 53(5):907-14. PubMed ID: 22023530
[TBL] [Abstract][Full Text] [Related]
18. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
Hirji I; Gupta S; Goren A; Chirovsky DR; Moadel AB; Olavarria E; Victor TW; Davis CC
Health Qual Life Outcomes; 2013 Oct; 11():167. PubMed ID: 24099272
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
